Additionally, we hypothesize that the efficacy of TMZ in G4 astrocytoma may improve with the use of PRMT5 inhibitors, irrespective of the methylation status of MGMT-promoter or IDH mutational status. Here, PRMT5 is linked to astrocytoma (excluding glioblastoma).